The MCK Enhancer Contains a P53 Responsive Element

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1991 Jun 1

PMID 1647009

Citations 58

Authors

H Weintraub

S Hauschka

S J Tapscott

Affiliations

Soon will be listed here.

Abstract

p53 is an antioncogene that is defective or absent in a large number of human tumors. Its function in normal cells is not known. We show that co-transfection of mouse p53 with muscle-specific creatine kinase-chloramphenicol acetyltransferase reporter gene, containing 3.3 kilobase of upstream control sequence for the muscle-specific creatine kinase gene, results in a 10- to 80-fold activation. The p53 responsive element maps to a region distinguished from the known MyoD binding region. Identification of a p53 responsive element should allow a more focused analysis of the effects of p53 in controlling gene activity.

Citing Articles

Alpha B-Crystallin in Muscle Disease Prevention: The Role of Physical Activity.

Dimauro I, Caporossi D Molecules. 2022; 27(3).

PMID: 35164412 PMC: 8840510. DOI: 10.3390/molecules27031147.

The ubiquitin-proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders.

Kitajima Y, Yoshioka K, Suzuki N J Physiol Sci. 2020; 70(1):40.

PMID: 32938372 PMC: 10717345. DOI: 10.1186/s12576-020-00768-9.

The Ubiquitin-Proteasome System Is Indispensable for the Maintenance of Muscle Stem Cells.

Kitajima Y, Suzuki N, Nunomiya A, Osana S, Yoshioka K, Tashiro Y Stem Cell Reports. 2018; 11(6):1523-1538.

PMID: 30416048 PMC: 6294073. DOI: 10.1016/j.stemcr.2018.10.009.

Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63.

von Grabowiecki Y, Abreu P, Blanchard O, Palamiuc L, Benosman S, Meriaux S Elife. 2016; 5.

PMID: 26919175 PMC: 4786414. DOI: 10.7554/eLife.10528.

p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress.

Yang Z, Broz D, Noderer W, Ferreira J, Overton K, Spencer S Cell Death Differ. 2014; 22(4):560-73.

PMID: 25501595 PMC: 4356341. DOI: 10.1038/cdd.2014.189.

References

Olson E . MyoD family: a paradigm for development?. Genes Dev. 1990; 4(9):1454-61. DOI: 10.1101/gad.4.9.1454. View

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

Johnson J, Wold B, Hauschka S . Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol Cell Biol. 1989; 9(8):3393-9. PMC: 362385. DOI: 10.1128/mcb.9.8.3393-3399.1989. View

Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View

Steinmeyer K, Deppert W . DNA binding properties of murine p53. Oncogene. 1988; 3(5):501-7. View

Eliyahu D, Michalovitz D, Eliyahu S, Oren M . Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A. 1989; 86(22):8763-7. PMC: 298370. DOI: 10.1073/pnas.86.22.8763. View

Linzer D, Levine A . Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979; 17(1):43-52. DOI: 10.1016/0092-8674(79)90293-9. View

Weintraub H, Tapscott S, Davis R, Thayer M, Adam M, Lassar A . Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A. 1989; 86(14):5434-8. PMC: 297637. DOI: 10.1073/pnas.86.14.5434. View

Fearon E, Hamilton S, Vogelstein B . Clonal analysis of human colorectal tumors. Science. 1987; 238(4824):193-7. DOI: 10.1126/science.2889267. View

10.

Eliyahu D, Michalovitz D, Oren M . Overproduction of p53 antigen makes established cells highly tumorigenic. Nature. 1985; 316(6024):158-60. DOI: 10.1038/316158a0. View

11.

Weintraub H, Davis R, Lockshon D, Lassar A . MyoD binds cooperatively to two sites in a target enhancer sequence: occupancy of two sites is required for activation. Proc Natl Acad Sci U S A. 1990; 87(15):5623-7. PMC: 54379. DOI: 10.1073/pnas.87.15.5623. View

12.

Raycroft L, Wu H, Lozano G . Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990; 249(4972):1049-51. PMC: 2935288. DOI: 10.1126/science.2144364. View

13.

Fields S, Jang S . Presence of a potent transcription activating sequence in the p53 protein. Science. 1990; 249(4972):1046-9. DOI: 10.1126/science.2144363. View

14.

Finlay C, Hinds P, Levine A . The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989; 57(7):1083-93. DOI: 10.1016/0092-8674(89)90045-7. View